FIELD: pharmacology.
SUBSTANCE: invention relates to compounds of formula (I) , where m equals 1 or 2; n equals 0, 1 or 2; each of R1 is independenly selected from the group consisting of C1-6alkyl, where C1-6alkyl is probably substitued with one R3; probably, two R1 are joint with a ring to which they are attached to form 8-membered heterobicycle; R3 is OR4; R4 is H; T0 is phenyl where T0 is substituted with the group N (R5a) C(O) N (R5bR5); R5a, R5b are independently selected from the group consisting of H; R5 is T2 or C1-6alkyl, where C1-6alkyl is probably substituted with 1-4 R8, which are the same or different; R8 is halogen; OR9; N (R9R9a); R9, R9a are independently selected from the group consisting of H; T2 is C3-7cycloalkyl; 4-6-membered heterocyclyl, wherein 1 circular atom is substituted with oxygen heteroatom; 6-membered aromatic heterocyclyl, wherein 1 circular atom is substituted with nitrogen heteroatom; and phenyl, wherein T2 is probably substituted with one or two R10, which are the same or different; R10 is halogen; OR11; or C1-6alkyl, where C1-6alkyl is probably substituted with one R12; R11 is H; R12 is OR13; R13 is H; T1 is phenyl or 6-membered aromatic heterocycle, wherein 1 carbon atom is substituted with nitrogen heteroatom, wherein T1 is substituted with a group S(O)2R14 and is probably additionally substituted with one R15; R15 is halogen; R14 is C1-6alkyl or unsubstituted 5-membered heterocyclyl ring, wherein 1 circular atom is substituted with nitrogen heteroatom. Compounds of formula (I) possess mTOR inhibitory activity. The invention also relates to a pharmaceutical composition, to compound application for drug manufacture and to a treatment method.
EFFECT: new compounds of formula are obtained, which are useful for treatment or prevention of mTOR-related diseases and disorders.
21 cl, 6 tbl, 44 ex
Title | Year | Author | Number |
---|---|---|---|
MORPHOLINO-SUBSTITUTED DERIVATIVES OF BICYCLIC PYRIMIDINE UREA OR CARBAMATE AS MTOR INHIBITORS | 2012 |
|
RU2609208C2 |
N-7 SUBSTITUTED PURINES AND PYRAZOLOPYRIMIDINES, COMPOSITIONS THEREOF AND METHODS FOR USE | 2010 |
|
RU2515541C2 |
N-9-SUBSTITUTED PURINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | 2010 |
|
RU2607635C2 |
TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGUES AND USE THEREOF AS THERAPEUTIC AGENTS AND DIAGNOSTIC SAMPLES | 2009 |
|
RU2537945C2 |
PYRROLO[2,1-f][1,2,4]TRIAZINE COMPOUND, METHOD FOR PRODUCTION AND USE THEREOF | 2013 |
|
RU2589053C1 |
APPLICATION OF S1P RECEPTOR AGONIST AND METHOD OF TREATMENT, ALLEVIATION OR RETARDATION OF OPTIC NEURITIS OR DEMYELINATING DISEASES PROGRESSION | 2003 |
|
RU2391094C2 |
ORGANIC COMPOUNDS | 2003 |
|
RU2478378C2 |
COMBINATION OF PYRIMIDYLAMINOBENZAMIDE AND mTOR KINASE INHIBITOR | 2006 |
|
RU2443418C2 |
MORPHOLINOPYRIMIDINE DERIVATIVES USEFUL FOR TREATING PROLIFERATIVE DISORDERS | 2007 |
|
RU2440349C2 |
COMBINED PRODUCTS CONTAINING TYROSINE KINASE INHIBITORS AND THEIR USE | 2013 |
|
RU2660354C2 |
Authors
Dates
2017-04-18—Published
2012-09-21—Filed